Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor

INTRODUCTION: The triple-combination (TC) cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimen elexacaftor, tezacaftor, and ivacaftor was shown to be safe and efficacious in phase 3 trials of people with cystic fibrosis (pwCF) ≥ 12 years of age with ≥ 1 F508del-CFTR allele. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Alice, Wu, Shu-Pei, Haseltine, Eric, Kumar, Sanjeev, Moskowitz, Samuel M., Panorchan, Paul, Shah, Kushal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672136/
https://www.ncbi.nlm.nih.gov/pubmed/32734574
http://dx.doi.org/10.1007/s41030-020-00124-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672136/
https://www.ncbi.nlm.nih.gov/pubmed/32734574
http://dx.doi.org/10.1007/s41030-020-00124-7

Ejemplares similares